pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Apr 30·1 min read
save

Investors at Boston Digital Healthcare Innovation Summit focus on emerging health tech opportunities

Apr 30, 2026·read at Endpoints ↗Neutral

The reporter attended the Digital Healthcare Innovation Summit in Boston earlier this week, gaining a firsthand view of investor perspectives on health technology.

Attendees heard that investors are closely watching emerging health tech trends and looking for promising opportunities, though specific areas were not detailed in the brief summary.

The article notes that full access to the complete coverage requires a subscription, encouraging readers to sign up for continued updates.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “What we heard at a health tech conference in Boston”

read at Endpoints ↗
83 words · retrieved Apr 30
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 2h agoGilead’s pill posts stronger colitis remission rates than EntyvioEndpoints
  • 2h agoEyePoint's Phase 3 failure; Lilly's China drug delivery dealEndpoints
  • 3h agoMerck KGaA to buy Silence Therapeutics and its siRNA pipeline for $1.3BEndpoints
  • 4h agoSanofi taps new startup ScionxBio for long-acting RNAEndpoints
  • 4h agoAbbVie’s Skyrizi combo beats Skyrizi alone in mid-stage Crohn’s trialEndpoints